(NASDAQ:REGN), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to […]

(NYSE:ZETA), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Zeta Global Holdings Corp. (NYSE: ZETA). Shareholders who purchased shares of ZETA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required

(NASDAQ:CELH), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Celsius Holdings, Inc. (NASDAQ: CELH). Shareholders who purchased shares of CELH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:MTCH), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Match Group, Inc. (NASDAQ: MTCH). Shareholders who purchased shares of MTCH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:SAVA), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:AZN), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

(NASDAQ:PCRX), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:XRX), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Xerox Holdings Corporation (NASDAQ: XRX). Shareholders who purchased shares of XRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

(NASDAQ:MQ), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Marqeta, Inc. (NASDAQ: MQ). Shareholders who purchased shares of MQ during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

(NasdaqGM:RVNC), NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to